Endpoints News 2026-02-13 Lilly appeals retatrutide classification ruling in case that could impact compounders
Endpoints News 2026-02-13 Lundbeck migraine prevention drug succeeds in Phase 2, advancing new therapy class
Endpoints News 2026-02-13 Paul Hudson couldn’t quite get Sanofi over the hump; PROTAC developer Arvinas appoints CEO
Endpoints News 2026-02-13 PTC Therapeutics withdraws US filing for troubled Duchenne treatment Translarna